Please provide your email address to receive an email when new articles are posted on . Penmenvy protects against meningococcal serotypes A, B, C, W and Y. CDC vaccine advisors are set to discuss ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the ...

Getting vaccinated for meningococcal disease lowers your risk of bacterial meningitis and other health problems. Stay updated on the latest vaccination recommendations to know when and how to get ...

Any infection caused by the Neisseria meningitidis (N. meningitidis) bacteria is called meningococcal disease. Meningococcal disease is very serious. It can lead to limb amputations, hearing loss, ...

GSK plc GSK announced that the U.S. Centers for Disease Control and Prevention’s (“CDC”) Advisory Committee on Immunization Practices (“ACIP”) voted favorably, recommending the use of Penmenvy ...

The ACIP voted that Penmenvy may be used as part of the adolescent meningococcal vaccination schedule as an alternative to separate administration of MenACWY and MenB. The Centers for Disease Control ...

The CDC’s Advisory Committee on Immunization Practices is expected to provide recommendations on the appropriate use of Penmenvy at its meeting on February 26, 2025. The Food and Drug Administration ...

(RTTNews) - GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 ...

Vaccine recommended to help protect persons over 10 years old in the United States (US) against disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y) Broad serogroup coverage in one ...

Approximately 1,300 Ohio State students might have been exposed to meningitis after a student tested positive for meningococcal disease last week. Kelli Newman, director of public affairs and ...